{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:50:24Z","timestamp":1792597824722,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2019"],"award-info":[{"award-number":["IG 2019"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115730","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T20:52:29Z","timestamp":1692219149000},"page":"115730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer"],"prefix":"10.1016","volume":"260","author":[{"given":"Davide","family":"Moi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Belluti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Linciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Citarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Imbriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-0607","authenticated-orcid":false,"given":"Giulio","family":"Rastelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115730_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"10.1016\/j.ejmech.2023.115730_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.juro.2016.04.029","article-title":"Re: comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy","volume":"196","author":"Penson","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.ejmech.2023.115730_bib3","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3390\/cancers13102426","article-title":"Novel target opportunities in non-metastatic castrate resistant prostate cancer","volume":"13","author":"Gleicher","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115730_bib4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115730_bib5","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-12-4414","article-title":"A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer","volume":"73","author":"Mitsiades","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115730_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"PREVAIL Investigators, Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115730_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"STAMPEDE investigators, Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115730_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.733202","article-title":"Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"11","author":"Mulati","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115730_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115730_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2023.115730_bib11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1210\/me.2009-0188","article-title":"HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer","volume":"23","author":"Ai","year":"2009","journal-title":"Mol. Endocrinol. Baltim. Md"},{"key":"10.1016\/j.ejmech.2023.115730_bib12","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.115730_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115730_bib15","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1039\/C9RA02985K","article-title":"Next-generation of selective histone deacetylase inhibitors","volume":"9","author":"Yang","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2023.115730_bib16","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1073\/pnas.140199597","article-title":"Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization","volume":"97","author":"Grozinger","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115730_bib17","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1582-4934.2011.01321.x","article-title":"Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis","volume":"15","author":"Clocchiatti","year":"2011","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115730_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115087","article-title":"Recent advances in class IIa histone deacetylases research","volume":"27","author":"Asfaha","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1139\/o01-032","article-title":"Class II histone deacetylases: structure, function, and regulation","volume":"79","author":"Bertos","year":"2001","journal-title":"Biochem. Cell Biol. Biochim. Biol. Cell."},{"key":"10.1016\/j.ejmech.2023.115730_bib20","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/MCB.20.18.6904-6912.2000","article-title":"Regulation of histone deacetylase 4 by binding of 14-3-3 proteins","volume":"20","author":"Wang","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115730_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2003.10.005","article-title":"Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate","volume":"45","author":"Halkidou","year":"2004","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2023.115730_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/me.2003-0065","article-title":"Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase","volume":"18","author":"Jeong","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2023.115730_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.biocel.2008.10.015","article-title":"Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers","volume":"41","author":"Ren","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115730_bib24","article-title":"Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease","author":"Wang","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2023.115730_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-1326-8-7","article-title":"HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?","volume":"8","author":"Sim\u00f5es-Pires","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2023.115730_bib26","article-title":"The role of HDAC6 in cancer","volume":"2011","author":"Aldana-Masangkay","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.115730_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/febs.12079","article-title":"Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes","volume":"280","author":"Li","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2023.115730_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115730_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2015.11.005","article-title":"4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90\u03b1 chaperone activity against prostate cancer","volume":"99","author":"Seidel","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115730_bib30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3389\/fcell.2020.00610","article-title":"Synergistic interaction of histone deacetylase 6- and MEK-inhibitors in castration-resistant prostate cancer cells","volume":"8","author":"Corno","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.115730_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13543776.2019.1708901","article-title":"A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)","volume":"30","author":"Shen","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115730_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.948217","article-title":"Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer","volume":"10","author":"Pramanik","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib33","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.18632\/aging.202554","article-title":"Discovery of a novel AR\/HDAC6 dual inhibitor for prostate cancer treatment","volume":"13","author":"Zhou","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2023.115730_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073401","article-title":"The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation","volume":"8","author":"Chuang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115730_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115730_bib36","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1021\/jm070178x","article-title":"Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies","volume":"50","author":"Kozikowski","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib37","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/jm4001659","article-title":"Development and therapeutic implications of selective histone deacetylase 6 inhibitors","volume":"56","author":"Kalin","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib38","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1074\/jbc.M116.771014","article-title":"Histone deacetylase (HDAC) inhibition induces I\u03baB kinase (IKK)-dependent interleukin-8\/CXCL8 expression in ovarian cancer cells","volume":"292","author":"Gatla","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbamcr.2012.12.002","article-title":"Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression","volume":"1833","author":"Jiang","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2023.115730_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2023.115730_bib41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3390\/ijms20040945","article-title":"Hydroxamic acid-based histone deacetylase (HDAC) inhibitors bearing a pyrazole scaffold and a cinnamoyl linker","volume":"20","author":"Zagni","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115730_bib42","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1021\/acs.jmedchem.8b01936","article-title":"Selective inhibition of histone deacetylase 10: hydrogen bonding to the gatekeeper residue is implicated","volume":"62","author":"G\u00e9raldy","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115730_bib44","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.1039\/D2RA01753A","article-title":"Synthesis of potent and selective HDAC6 inhibitors led to unexpected opening of a quinazoline ring","volume":"12","author":"Moi","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2023.115730_bib45","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.ejmech.2010.03.028","article-title":"Synthesis and biological evaluation of some thio containing pyrrolo [2,3-d]pyrimidine derivatives for their anti-inflammatory and anti-microbial activities","volume":"45","author":"Mohamed","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib46","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/acs.jmedchem.0c01717","article-title":"Design, synthesis, and activity evaluation of novel acyclic nucleosides as potential anticancer agents in vitro and in vivo","volume":"64","author":"Hao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib47","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.ejmech.2009.12.050","article-title":"Synthesis of new pyrrolo[2,3-d]pyrimidine derivatives and evaluation of their activities against human colon cancer cell lines","volume":"45","author":"Tangeda","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib48","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1021\/jm401899x","article-title":"Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells","volume":"57","author":"Lee","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib49","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of novel pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib50","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1021\/acs.jmedchem.1c02159","article-title":"Structure-based design and synthesis of N-substituted 3-Amino-\u03b2-Carboline derivatives as potent \u03b1\u03b2-tubulin degradation agents","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib51","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bmcl.2016.01.057","article-title":"Effects of a novel carbocyclic analog of pyrrolo[2,3-d]pyrimidine nucleoside on pleiotropic induction of cell death in prostate cancer cells with different androgen responsiveness","volume":"26","author":"Suh","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115730_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112291","article-title":"Purine\/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors","volume":"196","author":"Nepali","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104462","article-title":"Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs)","volume":"106","author":"Linciano","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib54","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/acsmedchemlett.8b00487","article-title":"Molecular basis for the selective inhibition of histone deacetylase 6 by a mercaptoacetamide inhibitor","volume":"9","author":"Porter","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115730_bib55","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib56","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41598-017-03417-1","article-title":"Novel class IIa-selective histone deacetylase inhibitors discovered using an in silico virtual screening approach","volume":"7","author":"Hsu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115730_bib57","article-title":"Dual targeting strategies on histone deacetylase 6 (HDAC6) and Heat Shock protein 90 (Hsp90)","author":"Bonanni","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib58","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1021\/acsomega.0c00559","article-title":"Design of dual inhibitors of histone deacetylase 6 and Heat Shock protein 90","volume":"5","author":"Pinzi","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2023.115730_bib59","doi-asserted-by":"crossref","DOI":"10.1021\/acsomega.1c03628","article-title":"Hydroxamic acid derivatives: from synthetic strategies to medicinal chemistry applications","volume":"6","author":"Citarella","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2023.115730_bib60","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/jm301355j","article-title":"Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif","volume":"56","author":"Wagner","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not Be the best histone deacetylase inhibitors--what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115730_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112887","article-title":"Mercaptoacetamide: a promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors","volume":"209","author":"Tavares","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib63","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1080\/14756366.2021.1981306","article-title":"Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group","volume":"36","author":"Linciano","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib64","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/jm400390r","article-title":"Discovery of the first histone deacetylase 6\/8 dual inhibitors","volume":"56","author":"Olson","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib65","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.jmedchem.5b01493","article-title":"Synthesis and biological investigation of oxazole hydroxamates as highly selective histone deacetylase 6 (HDAC6) inhibitors","volume":"59","author":"Senger","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib66","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115730_bib67","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115730_bib68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127023","article-title":"Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6","volume":"30","author":"Osko","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115730_bib70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","article-title":"Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group","volume":"9","author":"Lobera","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115730_bib71","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.jmb.2014.03.007","article-title":"Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen schistosoma mansoni","volume":"426","author":"Stolfa","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115730_bib72","series-title":"Schr\u00f6dinger Release 2021-1","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115730_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.v16i2.420","article-title":"Metronomic chemotherapy: changing the paradigm that more is better","volume":"16","author":"Scharovsky","year":"2009","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2023.115730_bib74","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2023.115730_bib75","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1124\/dmd.116.071514","article-title":"Hepatic clearance predictions from in vitro-in vivo extrapolation and the biopharmaceutics drug disposition classification system","volume":"44","author":"Bowman","year":"2016","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib76","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2023.115730_bib77","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.bmcl.2009.02.029","article-title":"N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetilase (HDAC) inhibitors","volume":"19","author":"Giannini","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115730_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113332","article-title":"Histone deacetylase 2: a potential therapeutic target for cancer and neurodegenerative disorders","volume":"216","author":"Gediya","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib79","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.drudis.2015.01.007","article-title":"Histone deacetylases: structural determinants of inhibitor selectivity","volume":"20","author":"Micelli","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115730_bib80","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115730_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000447813","article-title":"Comparative proteomics uncovers correlated signaling network and potential biomarkers for progression of prostate cancer","volume":"41","author":"Ai","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2023.115730_bib82","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2023.115730_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2013.05.020","article-title":"Class I HDACs share a common mechanism of regulation by inositol phosphates","volume":"51","author":"Millard","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115730_bib84","doi-asserted-by":"crossref","first-page":"26694","DOI":"10.1074\/jbc.M803514200","article-title":"Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain","volume":"283","author":"Bottomley","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib85","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib86","series-title":"Amber 2021","author":"Case","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115730_bib87","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.jcim.5b00674","article-title":"MCPB.py: a Python based metal center parameter builder","volume":"56","author":"Li","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.115730_bib88","doi-asserted-by":"crossref","DOI":"10.1063\/5.0005188","article-title":"Recent developments in the general atomic and molecular electronic structure system","volume":"152","author":"Barca","year":"2020","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2023.115730_bib89","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jcc.23881","article-title":"Comparison of structural, thermodynamic, kinetic and mass transport properties of Mg(2+) ion models commonly used in biomolecular simulations","volume":"36","author":"Panteva","year":"2015","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib90","doi-asserted-by":"crossref","first-page":"15460","DOI":"10.1021\/acs.jpcb.5b10423","article-title":"Force field for Mg 2+ , Mn 2+ , Zn 2+ , and Cd 2+ ions that have balanced interactions with nucleic acids","volume":"119","author":"Panteva","year":"2015","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2023.115730_bib91","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2023.115730_bib92","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1039\/c0cp00111b","article-title":"The R.E.D. tools: advances in RESP and ESP charge derivation and force field library building","volume":"12","author":"Dupradeau","year":"2010","journal-title":"Phys. Chem. Chem. Phys. PCCP."},{"key":"10.1016\/j.ejmech.2023.115730_bib93","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2023.115730_bib94","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13046-021-02166-4","article-title":"Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients","volume":"40","author":"Belluti","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115730_bib95","doi-asserted-by":"crossref","first-page":"45901","DOI":"10.18632\/oncotarget.9974","article-title":"NF-Y loss triggers p53 stabilization and apoptosis in HPV18-positive cells by affecting E6 transcription","volume":"7","author":"Benatti","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115730_bib96","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115730_bib97","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia N. Y. N."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:05:39Z","timestamp":1777529139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423006979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":97,"alternative-id":["S0223523423006979"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115730","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115730"}}